Catalyst
Slingshot members are tracking this event:
European Commission Approves Parsabiv (etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adults On Hemodialysis
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AMGN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 11, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Secondary Hyperparathyroidism, Hemodialysis, Parsabiv, Etelcalcetide, Chronic Kidney Disease
